• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Oscar Health Inc. (Amendment)

    2/14/24 4:15:59 PM ET
    $OSCR
    Medical Specialities
    Health Care
    Get the next $OSCR alert in real time by email
    SC 13G/A 1 d787985dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Oscar Health, Inc.

    (Name of Issuer)

    Class A Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

    687793109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 687793109   13G   Page 2 of 12

     

     1.   

     Names of Reporting Persons

     

     General Catalyst Group Management Holdings GP, LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     2,107,719

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     2,107,719

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,107,719

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.1%

    12.  

     Type of Reporting Person (See Instructions)

     

     OO


    CUSIP No. 687793109   13G   Page 3 of 12

     

     1.   

     Names of Reporting Persons

     

     General Catalyst Group Management Holdings, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     2,107,719

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     2,107,719

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,107,719

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.1%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN


    CUSIP No. 687793109   13G   Page 4 of 12

     

     1.   

     Names of Reporting Persons

     

     General Catalyst Group Management, LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     2,107,719

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     2,107,719

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,107,719

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.1%

    12.  

     Type of Reporting Person (See Instructions)

     

     OO


    CUSIP No. 687793109   13G   Page 5 of 12

     

     1.   

     Names of Reporting Persons

     

     General Catalyst GP X – Growth Venture, LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     2,107,719

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     2,107,719

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,107,719

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.1%

    12.  

     Type of Reporting Person (See Instructions)

     

     OO


    CUSIP No. 687793109   13G   Page 6 of 12

     

     1.   

     Names of Reporting Persons

     

     General Catalyst Partners X – Growth Venture, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     2,107,719

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     2,107,719

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,107,719

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.1%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN


    CUSIP No. 687793109   13G   Page 7 of 12

     

     1.   

     Names of Reporting Persons

     

     General Catalyst Group X – Growth Venture, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     USA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     2,107,719

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     2,107,719

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     2,107,719

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.1%

    12.  

     Type of Reporting Person (See Instructions)

     

     PN


    CUSIP No. 687793109   13G   Page 8 of 12

     

    Item 1.

     

      (a)

    Name of Issuer: Oscar Health, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    75 Varick Street, 5th Floor, New York, NY 10013

    Item 2.

     

      (a)

    Name of Person Filing:

    This joint statement on Schedule 13G is being filed by General Catalyst Group Management Holdings GP, LLC, a Delaware limited liability company (“GCGMH LLC”), General Catalyst Group Management Holdings, L.P., a Delaware limited partnership (“GCGMH”), General Catalyst Group Management, LLC, a Delaware limited liability company (“GCGM”), General Catalyst Group X – Growth Venture, L.P., a Delaware limited partnership (“GC X”), General Catalyst Partners X – Growth Venture, L.P., a Delaware limited partnership (“GC X GPLP”) and General Catalyst GP X – Growth Venture, LLC, a Delaware limited liability company (“GC X GPLLC”), collectively referred to herein as the “Reporting Persons.”

    GCGMH LLC is the general partner of GCGMH, which is the manager of GCGM, which is the manager of GC X GPLLC. GC X GPLP is the sole general partner of GC X. GC X GPLLC is the sole general partner of GC X GPLP.

    Both GCGMH LLC and GC X GPLLC are controlled by a group of three or more individuals, or the Managing Directors, having shared voting and dispositive control over the shares held by GC X. Under the so-called “rule of three,” because voting and dispositive decisions are made by a majority of both GCGMH LLC and GC X GPLLC Managing Directors, no one of the Managing Directors is deemed to be a beneficial owner of the Issuer’s securities held by GC X.

    The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13G as Exhibit 1 (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act.

    (b) Address of Principal Business Office or, if none, Residence: 20 University Road, 4th Floor, Cambridge, MA 02138

     

      (c)

    Citizenship:

    Each of GCGMH, GC X and GC X GPLP is a limited partnership organized under the laws of the State of Delaware. Each of GCGMH LLC, GCGM, a and GC X GPLLC is a limited liability company organized under the laws of the State of Delaware.

     

      (d)

    Title of Class of Securities:

    Class A Common Stock, $0.00001 par value per share.

     

      (e)

    CUSIP Number: 687793109

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 687793109   13G   Page 9 of 12

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned:

    GC X is the record owner of 2,107,719 shares (the “Record Shares”).

    As the general partner of GCGMH, GCGMH LLC may be deemed to beneficially own the Record Shares. As the sole general partner of GC X, GC X GPLP may be deemed to beneficially own the Record Shares. As the sole general partner of GC X GPLP, GC X GPLLC may be deemed to beneficially own the Record Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and managing directors, each Reporting Person may be deemed to share the power and direct the disposition and vote of the Record Shares.

    Both GCGMH LLC and GC X GPLLC are controlled by a group of three or more individuals, or the Managing Directors, having shared voting and dispositive control over the shares held by GC X. Under the so-called “rule of three,” because voting and dispositive decisions are made by a majority of both GCGMH LLC and GC X GPLLC Managing Directors, no one of the Managing Directors is deemed to be a beneficial owner of the Issuer’s securities held by GC X.

     

      (b)

    Percent of class:

    See Line 11 of cover sheets. The percentages set forth on the cover sheets for each Reporting Person are calculated based on 190,815,085 shares of Class A Common Stock reported to be outstanding by the Issuer as of October 31, 2023, as listed on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

      (c)

    Number of shares as to which the person has:

     

    (i)

    Sole power to vote or to direct the vote See Line 5 of cover sheets.

     

    (ii)

    Shared power to vote or to direct the vote See Line 6 of cover sheets.

     

    (iii)

    Sole power to dispose or to direct the disposition of See Line 7 of cover sheets.

     

    (iv)

    Shared power to dispose or to direct the disposition of See Line 8 of cover sheets.

    Each of the Reporting Persons disclaims beneficial ownership of such shares of Class A Common Stock except to the extent of its or his pecuniary interest therein, if any.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.


    CUSIP No. 687793109   13G   Page 10 of 12

     

    Item 8. Identification and Classification of Members of the Group.

    Not applicable

    Item 9. Notice of Dissolution of Group.

    Not applicable

    Item 10. Certification

    Not applicable. This statement on Schedule 13G is not filed pursuant to §240.13d-1(b) or §240.13d-1(c).

    Material to be Filed as Exhibits.

    Exhibit 1 – Agreement regarding joint filing of Schedule 13G.


    CUSIP No. 687793109   13G   Page 11 of 12

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    GENERAL CATALYST GROUP MANAGEMENT HOLDINGS GP, LLC
    By:   GENERAL CATALYST GROUP MANAGEMENT HOLDINGS, L.P.
      its General Partner
      By:   GENERAL CATALYST GROUP MANAGEMENT, LLC
        Its General Partner
        By:  

    /s/ Christopher McCain

        Christopher McCain
        Chief Legal Officer
    GENERAL CATALYST GROUP MANAGEMENT HOLDINGS, L.P.
    By:   GENERAL CATALYST GROUP MANAGEMENT, LLC
      its General Partner
        By:  

    /s/ Christopher McCain

        Christopher McCain
        Chief Legal Officer
    GENERAL CATALYST GROUP MANAGEMENT, LLC
        By:  

    /s/ Christopher McCain

        Christopher McCain
        Chief Legal Officer
    GENERAL CATALYST GROUP X – GROWTH VENTURE, L.P.
    By:   GENERAL CATALYST PARTNERS X—GROWTH VENTURE, L.P.
      its General Partner
      By:   GENERAL CATALYST GP X – GROWTH VENTURE, LLC
        its General Partner
        By:  

    /s/ Christopher McCain

          Christopher McCain
          Chief Legal Officer


    CUSIP No. 687793109   13G   Page 12 of 12

     

    GENERAL CATALYST PARTNERS X – GROWTH VENTURE, L.P.
    By:   GENERAL CATALYST GP X – GROWTH VENTURE, LLC
      its General Partner
      By:  

    /s/ Christopher McCain

        Christopher McCain
        Chief Legal Officer
    GENERAL CATALYST GP X – GROWTH VENTURE, LLC
      By:  

    /s/ Christopher McCain

        Christopher McCain
        Chief Legal Officer
    Get the next $OSCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSCR

    DatePrice TargetRatingAnalyst
    3/13/2025$20.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/10/2024$12.00Underperform
    Jefferies
    11/6/2024$21.00 → $13.50Neutral → Underperform
    BofA Securities
    10/7/2024$23.00Neutral
    UBS
    6/26/2024$25.00Overweight
    Piper Sandler
    5/30/2024$28.00Outperform
    Robert W. Baird
    5/30/2024$25.00 → $21.00Buy → Neutral
    BofA Securities
    3/22/2024$20.00Outperform
    Raymond James
    More analyst ratings

    $OSCR
    SEC Filings

    See more
    • SEC Form 144 filed by Oscar Health Inc.

      144 - Oscar Health, Inc. (0001568651) (Subject)

      5/12/25 4:09:55 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Oscar Health Inc.

      10-Q - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 7:11:20 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 6:24:47 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robinson Elbert O. Jr. sold $410,750 worth of shares (25,000 units at $16.43), decreasing direct ownership by 28% to 64,512 units (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      5/14/25 4:20:39 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Plouffe David

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:56 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Gassen William

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:43 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Leadership Updates

    Live Leadership Updates

    See more

    $OSCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $OSCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oscar Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York

      1/26/24 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Welcomes Two Healthcare Veterans to its Executive Leadership Team

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa

      9/6/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. Appoints Dr. Sean Martin, MD as New Chief Medical Officer

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built on a full stack technology platform, today announced that Dr. Sean Martin, MD has been appointed to serve as the company's new Chief Medical Officer, effective immediately. Dr. Martin joined Oscar in 2016 and during his tenure has provided clinical leadership across a number of core clinical functions, including enterprise affordability, medical management, market performance, population health, and behavioral health. In his new role, he will be responsible for implementing Oscar's clinical capabilities and enhancing the quality of care and outcomes for its members. "Dr. Martin is an avid champion of the us

      3/15/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

      With new backing from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE:OSCR), Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMin

      3/5/25 2:13:00 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Oscar Health from Overweight to Equal Weight and set a new price target of $16.00 from $20.00 previously

      3/13/25 8:18:37 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Jefferies initiated coverage on Oscar Health with a new price target

      Jefferies initiated coverage of Oscar Health with a rating of Underperform and set a new price target of $12.00

      12/10/24 7:59:30 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health downgraded by BofA Securities with a new price target

      BofA Securities downgraded Oscar Health from Neutral to Underperform and set a new price target of $13.50 from $21.00 previously

      11/6/24 7:54:31 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thrive Partners Vii Growth Gp, Llc bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:33:02 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Co-Founder and Vice Chairman Kushner Joshua bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:29:47 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Director Thrive Partners Vii Growth Gp, Llc bought $5,444,343 worth of shares (344,522 units at $15.80) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/18/24 5:02:12 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oscar Health Inc.

      SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 4:07:27 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Oscar Health Inc.

      SC 13G - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 1:28:35 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Oscar Health Inc.

      SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)

      11/13/24 9:24:55 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Financials

    Live finance-specific insights

    See more
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Announces Fourth Quarter and Full Year 2024 Results; Introduces Full Year 2025 Outlook

      Reports Adjusted EBITDA and Net Income Profitability for the First Time in Company History For the year ended December 31, 2024: Total Revenue of $9.2 billion, a 56.5% increase year-over-year Medical Loss Ratio of 81.7%, a 10 bps increase year-over-year SG&A Expense Ratio of 19.1%, a 520 bps improvement year-over-year Net income attributable to Oscar of $25.4 million, or $0.10 of diluted earnings per share, a $296.2 million improvement year-over-year Adjusted EBITDA of $199.2 million, an improvement of $244.5 million year-over-year Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results

      2/4/25 4:05:00 PM ET
      $OSCR
      Medical Specialities
      Health Care